Evaluation of Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Patients with Metastatic Castration-Resistant Prostate Cancer

The primary objective of this study is to evaluate the **safety** and **pharmacokinetics** of AMX-500 in patients with metastatic castration-resistant prostate cancer (mCRPC), also known as **hormone-refractory prostate cancer**. This is clinically relevant as understanding the safety profile and pharmacokinetic properties of AMX-500 is crucial for determining its potential as a therapeutic option for patients with this advanced form of prostate cancer. The study aims to provide insights into how the drug is absorbed, distributed, metabolized, and excreted in the body, which is essential for optimizing dosing regimens and minimizing adverse effects.

The clinical trial involves a total of **159 participants** diagnosed with **hormone-refractory prostate cancer**. The study population is exclusively male, with an age range that includes both middle-aged and older adults. Participants were selected based on specific criteria, although the principal inclusion criteria were not provided by the sponsor. The trial does not include vulnerable populations. Lifestyle factors such as diet, physical activity, or habits were not specified in the available data. The selection process aimed to ensure a representative sample of the target demographic, focusing on individuals with the specified medical condition.

The clinical trial is designed to evaluate the **safety**, pharmacokinetics, and preliminary efficacy of AMX-500 in patients with **hormone-refractory prostate cancer**. This study is a Phase 1 trial, which will be conducted as a randomized, double-blind, and controlled trial. The estimated recruitment start date is November 1, 2023, with an anticipated end date of May 1, 2027. The trial will involve multiple study visits, beginning with an inclusion visit where participants will be screened for eligibility based on specific criteria. This visit will ensure that only suitable candidates are enrolled in the study.

Following the inclusion visit, participants will undergo a series of follow-up visits at predetermined intervals. These visits are crucial for monitoring the participants' health, assessing the pharmacokinetics of AMX-500, and evaluating any adverse effects. The follow-up visits will also involve collecting data to assess the preliminary efficacy of the treatment. The end-of-study visit will mark the conclusion of the participant's involvement in the trial, where final assessments will be conducted to gather comprehensive data on the treatment's impact.

The expected length of participant involvement will vary depending on individual response and the overall trial timeline. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study protocols, or withdraw consent. The trial's design ensures that all procedures are conducted in a manner that prioritizes participant safety and the integrity of the collected data.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is November 1, 2023, with an anticipated end date of May 1, 2027. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to gather data on the investigational product's effects. The schedule for measuring and collecting efficacy data is typically aligned with the trial's protocol, ensuring systematic and consistent data collection throughout the study duration. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the investigational product's potential benefits. The trial's findings will contribute to the understanding of the investigational product's efficacy profile, guiding future research phases.